HUTCHMED Highlights HMPL-A830 Pre-Clinical Data

Summary by AI BETAClose X

HUTCHMED reported preclinical data for HMPL-A830 showing potent pan‑KRAS payload activity across 55 tumor cell lines with dual‑action inhibition of KRAS “ON” and “OFF” states, high EGFR affinity, rapid internalization, bystander killing and maintained ADCC; in mouse models HMPL‑A830 produced dose‑dependent robust antitumor efficacy and more durable regressions than KRAS G12C inhibitors, with stable drug‑to‑antibody ratio in mouse, monkey and human plasma; HMPL‑A830 targets KRAS mutations present in ~44% of colorectal cancer, ~34% of lung adenocarcinoma and up to ~89% of pancreatic ductal adenocarcinoma; Phase Ia (NCT07718581) is ongoing and HUTCHMED granted GSK rights outside Mainland China, Hong Kong, Macau and Taiwan in September 2026.

Disclaimer*

UK 100

Latest directors dealings